Genetic Tests
Cancer is a treatable disease when detected in the early stages. We help individuals determine their cancer risk through genetic testing. Using the latest technology and scientific research, our team of experts assesses cancer risk based on a person's genetic profile, allowing you to take early precautions.
Simple Integration
Simple Integration Order the test, Proteocyte does the rest!
No Additional Biopsy
No Additional Biopsy Uses patient’s original biopsy tissue
5-Year Risk Score
Accurate, objective, individualized. Sensitivity of 97% and a NPV of 97%.
Clinical Need
Oral cancer affects 450,000 people/year worldwide with a 5-year mortality rate of ~50%, predominantly due to late diagnosis. Late stage cancers are more costly and difficult to treat.
The standard of care for OPMD (oral potentially malignant disorder) risk assessment is dysplasia grading by histopathology. Historically, histopathology is impacted by both intra’ and inter-observer variation, as well as significant overlap between grades, impacting its usefulness as a prognostic tool.
Such limitations have led to a widely recognized and urgent need for more effective prognostic biomarkers among clinicians who treat oral cancer and OPMD.
